Vorhofflimmern: Rhythmus- oder Frequenzkontrolle?

Zusammenfassung

Es gibt unterschiedliche Therapiepfade, die bei der Behandlung von Vorhofflimmern beschritten werden können. Die Wahl ist abhängig von der Entität des Vorhofflimmerns, Komorbiditäten, strukturellen Herzerkrankungen und nicht zuletzt dem Patientenwunsch. Erfahren Sie, welche Aspekte wichtig sind, um einen individuellen Behandlungsplan für Ihre Patienten zu erstellen.

Abstract

In the face of current demographic developments the incidence of atrial fibrillation is increasing. Depending on comorbidities, structural heart disease and patient choice different treatment strategies can be followed. Learn about the aspects that are important in choosing a tailored, evidence-based treatment of atrial fibrillation for your patient.

Schlüsselwörter

Vorhofflimmern - Frequenzkontrolle - Rhythmuskontrolle

Keywords

atrial fibrillation - rate control - rhythm control

• Literatur

• 1 Schnabel RB, Wilde S, Wild PS et al. Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int 2012; 109: 293-299
• 2 Krijthe BP, Kunst A, Benjamin EJ et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34: 2746-2751
• 3 Nishida K, Datino T, Macle L et al. Atrial fibrillation ablation: translating basic mechanistic insights to the patient. J Am Coll Cardiol 2014; 64: 823-831
• 4 Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of Atrial Fibrillation. JAMA 2015; 314: 278-288
• 5 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
• 6 Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012; 126: 860-865
• 7 Kirchhof P, Goette A, Gulba D et al. Kommentar zu den Leitlinien der ESC zum Vorhofflimmern. Kardiologe 2012; 6: 12-27
• 8 Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840
• 9 Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513
• 10 Fey H, Jost M, Geise AT et al. Kardiogener Schock nach bradykardisierender Therapie bei tachykardem Vorhofflimmern. Med Klin Intensivmed Notfmed 2015; 111: 458-462
• 11 Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 2014; 16: 162-173
• 12 Crijns HJ, Weijs B, Fairley AM et al. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol 2014; 172: 588-594
• 13 Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004; 35: 2384-2391
• 14 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
• 15 Jons C, Hansen PS, Johannessen A et al. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. Europace 2009; 11: 917-923
• 16 Morillo CA, Verma A, Connolly SJ et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014; 311: 692-700
• 17 Luik A, Radzewitz A, Kieser M et al. Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. Circulation 2015; 132: 1311-1319
• 18 Kuck KH, Brugada J, Fürnkranz A et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med 2016; 374: 2235-2245
• 19 Dukkipati SR, Cuoco F, Kutinsky I et al. Pulmonary Vein Isolation Using the Visually Guided Laser Balloon: A Prospective, Multicenter, and Randomized Comparison to Standard Radiofrequency Ablation. J Am Coll Cardiol 2015; 66: 1350-1360
• 20 Schreiber D, Rostock T, Fröhlich M et al. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol. 2015; 8: 308-317
• 21 Boveda S, Providência R, Defaye P et al. Outcomes after cryoballoon or radiofrequency ablation for persistent atrial fibrillation: a multicentric propensity-score matched study. J Interv Card Electrophysiol 2016;
• 22 Vogler J, Willems S, Sultan A et al. Pulmonary Vein Isolation Versus Defragmentation: The CHASE-AF Clinical Trial. J Am Coll Cardiol 2015; 66: 2743-2752
• 23 Verma A, Jiang CY, Betts TR et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015; 372: 1812-1822
• 24 Narayan SM, Krummen DE, Shivkumar K et al. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012; 60: 628-636
• 25 Mohanty S, Gianni C, Mohanty P et al. Impact of Rotor Ablation in Non-Paroxysmal AF Patients: Results from a Randomized Trial (OASIS). J Am Coll Cardiol 2016; 68: 274-282
• 26 Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373
• 27 Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011; 365: 2268-2276
• 28 January CT, Wann LS, Alpert JS et al. 2014 AHA / ACC / HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology / American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-267
• 29 Brignole M, Auricchio A, Baron-Esquivias G et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013; 15: 1070-1118
• 30 Chatterjee NA, Upadhyay GA, Ellenbogen KA et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012; 5: 68-76
• 31 Chatterjee NA, Upadhyay GA, Ellenbogen KA et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail 2012; 14: 661-667
• 32 Orlov MV, Gardin JM, Slawsky M et al. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J 2010; 159: 264-270